Skip to main content
logo
C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.490
+0.010 (0.29%)
Aug 3, 2026, 10:26 AM EDT - Market open

C4 Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2022FY 2021FY 2020
Period EndingDec '25 Dec '25 Dec '24 Dec '22 Dec '21 Dec '20
Revenue
35.9535.9535.5831.145.7933.2
Revenue Growth
32.15%1.02%14.43%-32.08%37.93%55.25%
Gross Profit
35.9535.9535.5831.145.7933.2
Operating Income
-115.22-115.22-119.61-129.53-82.13-60.45
Net Income
-104.99-104.99-105.32-128.18-83.89-66.34
Earnings Per Share
-1.27-1.27-1.52-2.62-1.82-5.83
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2022FY 2021FY 2020
Period EndingMar '26 Dec '25 Dec '24 Dec '22 Dec '21 Dec '20
Cash & Investments
235.67248.54244.9276.15309.28371.69
Total Debt
58.4559.9865.7687.1542.8822.92
Net Cash (Debt)
177.22188.56179.15189266.4348.77
Net Cash Growth
-1.07%5.25%-5.21%-29.05%-23.62%354.13%
Net Cash Per Share
1.702.272.583.875.7930.67

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2022FY 2021FY 2020
Period EndingDec '25 Dec '25 Dec '24 Dec '22 Dec '21 Dec '20
Operating Cash Flow
-98.69-98.69-65.16-105.94-86.97-67.25
Capital Expenditures
-0.61-0.61-0.18-5.5-1.28-0.65
Free Cash Flow
-99.3-99.3-65.34-111.44-88.24-67.9
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2022FY 2021FY 2020
Period EndingDec '25 Dec '25 Dec '24 Dec '22 Dec '21 Dec '20
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-320.53%-320.53%-336.14%-416.56%-179.39%-182.10%
Pretax Margin
-291.74%-291.74%-295.60%-412.19%-183.23%-201.72%
Profit Margin
-291.74%-291.74%-295.60%-412.19%-183.23%-199.83%
FCF Margin
-276.24%-276.24%-183.61%-358.36%-192.73%-204.55%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2022FY 2021FY 2020
Period EndingAug '26 Dec '25 Dec '24 Dec '22 Dec '21 Dec '20
PS Ratio
11.045.157.15---